Literature DB >> 21753853

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

Andrea Facciabene1, Xiaohui Peng, Ian S Hagemann, Klara Balint, Andrea Barchetti, Li-Ping Wang, Phyllis A Gimotty, C Blake Gilks, Priti Lal, Lin Zhang, George Coukos.   

Abstract

Although immune mechanisms can suppress tumour growth, tumours establish potent, overlapping mechanisms that mediate immune evasion. Emerging evidence suggests a link between angiogenesis and the tolerance of tumours to immune mechanisms. Hypoxia, a condition that is known to drive angiogenesis in tumours, results in the release of damage-associated pattern molecules, which can trigger the rejection of tumours by the immune system. Thus, the counter-activation of tolerance mechanisms at the site of tumour hypoxia would be a crucial condition for maintaining the immunological escape of tumours. However, a direct link between tumour hypoxia and tolerance through the recruitment of regulatory cells has not been established. We proposed that tumour hypoxia induces the expression of chemotactic factors that promote tolerance. Here we show that tumour hypoxia promotes the recruitment of regulatory T (T(reg)) cells through induction of expression of the chemokine CC-chemokine ligand 28 (CCL28), which, in turn, promotes tumour tolerance and angiogenesis. Thus, peripheral immune tolerance and angiogenesis programs are closely connected and cooperate to sustain tumour growth. ©2011 Macmillan Publishers Limited. All rights reserved

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21753853     DOI: 10.1038/nature10169

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  37 in total

1.  Multiple initial culture conditions enhance the establishment of cell lines from primary ovarian cancer specimens.

Authors:  Cara C Bertozzi; Cheng-Yi Chang; Sonya Jairaj; Xiaochuan Shan; Jia Huang; Barbara L Weber; Christina S Chu; Richard G Carroll
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Mar-Apr       Impact factor: 2.416

Review 2.  Endothelin B receptor, a new target in cancer immune therapy.

Authors:  Lana E Kandalaft; Andrea Facciabene; Ron J Buckanovich; George Coukos
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

3.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

Review 4.  Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors.

Authors:  Ramin Lotfi; James J Lee; Michael T Lotze
Journal:  J Immunother       Date:  2007-01       Impact factor: 4.456

5.  Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia-ischemia.

Authors:  M Bergeron; S M Evans; F R Sharp; C J Koch; E M Lord; D M Ferriero
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

6.  A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues.

Authors:  J Pan; E J Kunkel; U Gosslar; N Lazarus; P Langdon; K Broadwell; M A Vierra; M C Genovese; E C Butcher; D Soler
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

7.  Redundant role of chemokines CCL25/TECK and CCL28/MEC in IgA+ plasmablast recruitment to the intestinal lamina propria after rotavirus infection.

Authors:  Ningguo Feng; María C Jaimes; Nicole H Lazarus; Denise Monak; Caiqui Zhang; Eugene C Butcher; Harry B Greenberg
Journal:  J Immunol       Date:  2006-05-15       Impact factor: 5.422

8.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

9.  The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

Authors:  Takuya Osada; Gabriel Chong; Robert Tansik; Timothy Hong; Neil Spector; Rakesh Kumar; Herbert I Hurwitz; Inderjit Dev; Andrew B Nixon; H Kim Lyerly; Timothy Clay; Michael A Morse
Journal:  Cancer Immunol Immunother       Date:  2008-01-10       Impact factor: 6.968

10.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

View more
  491 in total

Review 1.  HIF transcription factors, inflammation, and immunity.

Authors:  Asis Palazon; Ananda W Goldrath; Victor Nizet; Randall S Johnson
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

2.  Rethinking ovarian cancer: recommendations for improving outcomes.

Authors:  Sebastian Vaughan; Jermaine I Coward; Robert C Bast; Andy Berchuck; Jonathan S Berek; James D Brenton; George Coukos; Christopher C Crum; Ronny Drapkin; Dariush Etemadmoghadam; Michael Friedlander; Hani Gabra; Stan B Kaye; Chris J Lord; Ernst Lengyel; Douglas A Levine; Iain A McNeish; Usha Menon; Gordon B Mills; Kenneth P Nephew; Amit M Oza; Anil K Sood; Euan A Stronach; Henning Walczak; David D Bowtell; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

Review 3.  CCR10 and its ligands in regulation of epithelial immunity and diseases.

Authors:  Na Xiong; Yaoyao Fu; Shaomin Hu; Mingcan Xia; Jie Yang
Journal:  Protein Cell       Date:  2012-06-08       Impact factor: 14.870

4.  Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells.

Authors:  Y You; Y Li; M Li; M Lei; M Wu; Y Qu; Y Yuan; T Chen; H Jiang
Journal:  Clin Exp Immunol       Date:  2017-10-23       Impact factor: 4.330

5.  Colon cancer stem cells: Potential target for the treatment of colorectal cancer.

Authors:  Riya Gupta; Lokesh Kumar Bhatt; Thomas P Johnston; Kedar S Prabhavalkar
Journal:  Cancer Biol Ther       Date:  2019-05-03       Impact factor: 4.742

6.  Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma.

Authors:  Richard W Joseph; Mansi Parasramka; Jeanette E Eckel-Passow; Dan Serie; Kevin Wu; Liuyan Jiang; Krishna Kalari; R Houston Thompson; Thai Huu Ho; Erik P Castle; John Cheville; Eugene D Kwon; E Aubrey Thompson; Alexander Parker
Journal:  Cancer Immunol Res       Date:  2013-08-29       Impact factor: 11.151

7.  Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation.

Authors:  C Andrew Stewart; Hannah Metheny; Noriho Iida; Loretta Smith; Miranda Hanson; Folkert Steinhagen; Robert M Leighty; Axel Roers; Christopher L Karp; Werner Müller; Giorgio Trinchieri
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

Review 8.  Regulatory T cells in nonlymphoid tissues.

Authors:  Dalia Burzyn; Christophe Benoist; Diane Mathis
Journal:  Nat Immunol       Date:  2013-09-18       Impact factor: 25.606

9.  Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.

Authors:  Rafael Carretero; Ibrahim M Sektioglu; Natalio Garbi; Oscar C Salgado; Philipp Beckhove; Günter J Hämmerling
Journal:  Nat Immunol       Date:  2015-04-27       Impact factor: 25.606

10.  Hypoxia promotes the proliferation of cervical carcinoma cells through stimulating the secretion of IL-8.

Authors:  Li-Bing Liu; Feng Xie; Kai-Kai Chang; Ming-Qing Li; Yu-Han Meng; Xiao-Hui Wang; Hui Li; Da-Jin Li; Jin-Jin Yu
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.